Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment
27 10월 2023 - 2:40PM
Dow Jones News
By Adria Calatayud
Roche Holding said it received approval from the U.S. Food and
Drug Administration for Vabysmo as treatment of macular edema
following retinal vein occlusion, the drug's third indication.
The Swiss pharmaceutical giant said Friday that the approval was
based on two late-stage studies that demonstrated early and
sustained vision improvements.
Vabysmo is already approved for so-called "wet" age-related
macular degeneration and diabetic macular edema, Roche said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 27, 2023 01:25 ET (05:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Roche Holdings Ltd AG (QX) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Roche Holdings Ltd AG (QX) News Articles